

Global Chronic Kidney Disease - Major Players are Focusing on New Treatment Strategies, New Report 2017-2022

PUNE, INDIA, March 16, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026"

Chronic Kidney Disease

Overview

Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time (NIH, 2010). As the disease progresses, the symptoms worsen, eventually leading to kidney failure (NIH, 2010). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.

In the 7MM, epidemiologists forecast the diagnosed prevalent cases of CKD, Stages I-V, to increase from 25,775,828 cases in 2016 to 28,325,839 cases in 2026, at an Annual Growth Rate (AGR) of 0.99%. The UK will have the highest number of diagnosed cases of CKD throughout the forecast period.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2879267-pharmafocus-supportive-care-in-Chronic Kidney Disease

Scope

- The Chronic Kidney Disease EpiCast Report provides an overview of the risk factors and global trends of chronic kidney disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.
- The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Kidney Disease EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease treatment market.
- Quantify patient populations in the chronic kidney disease market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic kidney disease therapeutics in each of the markets covered.

- Understand magnitude of chronic kidney disease.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2879267-pharmafocus-supportive-care-in-Chronic Kidney Disease

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent WiseGuy Research Consultants Pvt. Ltd. +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.